Table 3.
Toxicity of study drugs and interventions
| Intervention | Adverse reaction | n | % |
| Surgery (grades 3 and 4) | Chylos | 1 | 4 |
| Chemotherapy (grades 3 and 4) | Neutropenia | 25 | 100 |
| Trombocytopenia | 22 | 88 | |
| Anemia | 22 | 88 | |
| Infection | 6 | 24 | |
| Nausea | 2 | 8 | |
| Hyponatremia | 2 | 8 | |
| Hemorrhagic cystitis | 1 | 4 | |
| Fatigue | 1 | 4 | |
| Vertigo | 1 | 4 | |
| PS drop | 1 | 4 | |
| Thrombosis in CVC | 1 | 4 | |
| TIL infusion (grades 3 and 4) | Fever | 4 | 16 |
| Dyspnea | 2 | 8 | |
| PS drop | 3 | 12 | |
| Transaminase elevation | 1 | 4 | |
| IL-2 (grades 3 and 4) | Fever | 16 | 64 |
| Fatigue | 5 | 20 | |
| PS drop | 4 | 16 | |
| Dyspnea | 4 | 16 | |
| Transaminase elevation | 2 | 8 | |
| Vomiting | 2 | 8 | |
| Elevated creatinine | 1 | 4 | |
| Hallucinations | 1 | 4 | |
| IrAEs (grades 3 and 4) | Fever | 2 | 8 |
| Hepatitis | 2 | 8 | |
| Colitis | 2 | 8 | |
| Thyroiditis | 3 | 12 | |
| IrAEs (grades 1 and 2) | Parotidis | 1 | 4 |
| Hepatitis | 1 | 4 | |
| Adrenilitis | 1 | 4 | |
| Dermatitis | 1 | 4 | |
| Myalgia | 1 | 4 |
Grades 3 and 4 (CTCAE V.4.1) treatment related adverse events. IrAEs of all grades after checkpoint inhibitors are shown.
CVC, Central venous catheter; IL, interleukin; IrAE, immune-related adverse event; PS, performance status; TIL, tumor-infiltrating lymphocyte.